NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 247)
Posted On: 01/14/2022 2:49:42 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing the effectiveness of orally administered drugs. With oral absorption being the most convenient and widely used route for taking medications, decades of research have advanced the understanding of critical factors controlling oral bioavailability. Scientists are now better understanding the physiological function and formulation functionality that has been used in designing improved and more desirable oral medicine delivery through extensive research. Lexaria is accomplishing this through its patented DehydraTECH(TM) technology. “DehydraTECH improves the way that active pharmaceutical ingredients (‘APIs’) make their way into the bloodstream. This is achieved by promoting healthier ingestion methods and an increase in the effectiveness of fat-soluble active molecules,” explains a recent article. “Lexaria’s DehydraTECH can be summarized by these major benefits: speeds up delivery; increases bioavailability; increases brain absorption; improves drug potency; reduces drug administration costs; and masks unwanted taste. One of Lexaria’s recent human clinical trials (HYPER-H21-2) using DehydraTECH-processed cannabidiol (‘CBD’) evidenced reduced arterial stiffness. The discovery potentially broadens Lexaria’s application’s ability to treat cardiovascular and other diseases beyond hypertension.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing the effectiveness of orally administered drugs. With oral absorption being the most convenient and widely used route for taking medications, decades of research have advanced the understanding of critical factors controlling oral bioavailability. Scientists are now better understanding the physiological function and formulation functionality that has been used in designing improved and more desirable oral medicine delivery through extensive research. Lexaria is accomplishing this through its patented DehydraTECH(TM) technology. “DehydraTECH improves the way that active pharmaceutical ingredients (‘APIs’) make their way into the bloodstream. This is achieved by promoting healthier ingestion methods and an increase in the effectiveness of fat-soluble active molecules,” explains a recent article. “Lexaria’s DehydraTECH can be summarized by these major benefits: speeds up delivery; increases bioavailability; increases brain absorption; improves drug potency; reduces drug administration costs; and masks unwanted taste. One of Lexaria’s recent human clinical trials (HYPER-H21-2) using DehydraTECH-processed cannabidiol (‘CBD’) evidenced reduced arterial stiffness. The discovery potentially broadens Lexaria’s application’s ability to treat cardiovascular and other diseases beyond hypertension.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼